GILD

Gilead Sciences, Inc.

Healthcare
127.57 -3.53 -2.69% Market Closed
2026-06-02 • USD

Key Metrics

Market Cap 158.39B
EV —
Shares Out 1.24B
Revenue (ttm) 29.74B
Net Income 9.22B
Beta —
P/E 17.19
Forward P/E —
EPS (ttm) $7.35
P/S 5.33
P/B 6.74
P/FCF —
P/C —
EV/Sales —
EV/EBITDA —
ROA 16.38%
ROE 42.76%
ROIC 18.96%
Gross Margin —
Oper. Margin 34.88%
Profit Margin 30.99%
Debt/Eq 1.00
LT Debt/Eq 47.01%
Quick Ratio —
Current Ratio 1.97
Book/sh 18.93
Cash/sh —
Div Yield 2.52%
Div TTM $3.22
Payout Ratio 43.81%
SMA20 -3.75%
SMA50 -5.3%
SMA200 -0.92%
Volume 8,082,551
Avg Volume 6.76M
Rel Volume —
Perf Week -5.10%
Perf Month -4.43%
Perf Quarter -12.11%
Perf Half Y 5.24%
Perf YTD 3.94%
Perf Year 15.49%
Perf 3Y 64.14%
Perf 5Y 89.19%

Factor Lens

Seasonal Performance

Dividends

Per-share amounts adjusted for stock splits.

Last Dividend $0.8200
TTM Yield 2.52%
TTM Amount $3.22
Payout Ratio 43.81%
3-Yr Growth (CAGR) 2.67%
5-Yr Growth (CAGR) 3.04%

Last 12 Payouts

Period Ex-Date Amount / Share
Q1 2026 ~2026-06-29 $0.8200
Q1 2026 ~2026-03-30 $0.8200
Q3 2025 ~2025-12-30 $0.7900
Q2 2025 ~2025-09-29 $0.7900
Q1 2025 ~2025-06-27 $0.7900
Q1 2025 ~2025-03-28 $0.7900
Q3 2024 ~2024-12-30 $0.7700
Q2 2024 ~2024-09-27 $0.7700
Q1 2024 ~2024-06-27 $0.7700
Q1 2024 ~2024-03-28 $0.7700
Q3 2023 ~2023-12-28 $0.7500
Q2 2023 ~2023-09-28 $0.7500

Financial Trends

Revenue & Net Income

Earnings Per Share

Margins

Cash Flow

Company Overview

Gilead Sciences, Inc. is a research-based biopharmaceutical company with a mission to discover, develop and deliver innovative therapeutics for people with life-threatening diseases. The company operates through multiple therapeutic areas: (1) HIV, where Gilead is a leader in treatment and prevention with products including Biktarvy (the most-prescribed HIV treatment regimen), Descovy for PrEP, and Yeztugo (the first twice-yearly HIV PrEP); (2) Oncology, with products such as Trodelvy for metastatic triple-negative breast cancer and investigational cell therapies like anito-cel; (3) Liver Disease, including Livdelzi for primary biliary cholangitis and Vemlidy for chronic hepatitis B; and (4) Inflammation and other therapeutic areas. In 2025, the company generated total product sales of $28.9 billion, with HIV product sales of $20.8 billion representing 6% year-over-year growth. Gilead maintains a pipeline of 53 clinical-stage programs as of the end of 2025, with potential for up to 10 ongoing and near-term product or indication launches by the end of 2027. The company is committed to expanding global access to its medicines and announced partnerships with PEPFAR and the Global Fund to supply lenacapavir for HIV prevention to up to two million people in low- and lower-middle-income countries.

Name
Gilead Sciences, Inc.
Industry
Biotechnology
CEO
Daniel P. O'Day · Chairman and Chief Executive Officer
Employees
—
IPO Date
2017-11-20
Phone
6505743000
Address
333 Lakeside Drive, Foster City, CA 94404
Website
www.gilead.com

Key Executives

Name Title FY Pay
Kelly A. Kramer Director —
Sandra J. Horning Director —
Jeffrey A. Bluestone Director —
Jacqueline K. Barton Director —
Daniel P. O'Day Chairman and Chief Executive Officer —

Latest News